Journal
ACTA PHARMACOLOGICA SINICA
Volume 35, Issue 4, Pages 433-443Publisher
ACTA PHARMACOLOGICA SINICA
DOI: 10.1038/aps.2013.188
Keywords
microvesicles; microparticles; diabetes; thrombosis; vascular inflammation; endothelial dysfunction; angiogenesis; diabetic nephropathy; diabetic retinopathy; cardiovascular disease
Funding
- National Natural Science Foundation of China (NSFC) [81273915, 81072922]
- American Heart Association (AHA)
- Temple University Department of Medicine Career Development Award
Ask authors/readers for more resources
Microvesicles (MVs), also known as microparticles, are small membrane vesicles released from different cell types under different conditions. MVs have been detected in the circulation and in organs/ tissues in various diseases, including diabetes. Patients with different types of diabetes and complications have different cellular MV patterns. Studies have shown that MVs may mediate vascular thrombosis, vascular inflammation, angiogenesis, and other pathological processes of the disease through their procoagulant, proinflammatory, pro-angiogenic, proteolytic, and other properties. Therefore, MVs contribute to the development of diabetic macrovascular and microvascular complications. In addition, clinical studies have indicated that changes in MV number and composition may reflect the pathophysiological conditions of disease, and therefore, may serve as potential biomarkers for diagnostic and prognostic use. Understanding MVs' involvement in the pathophysiological conditions may provide insight into disease mechanisms and would also be helpful for the development of novel therapeutic strategies in the future. Here, we review the latest publications from our group and other groups and focus on the involvement of MVs in diabetic complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available